Maire Jung

VP & CSO, RNA, Lilly Institute of Genetic Medicine, Eli Lilly and Company

Dr. Maire Jung is Vice President and Chief Scientific Officer of RNA within the Institute of Genetic Medicine at Eli Lilly and Company, where she leads a cross-functional team of biologists, chemists, and computational biologists committed to delivering oligonucleotide-based drugs to the clinic.  

Dr. Jung joined Lilly in 2022. Prior to her role at Lilly, she led the neuroscience and ophthalmology group at Dicerna Pharmaceuticals, which was acquired by Novo Nordisk in 2021. Prior to joining Dicerna, Dr. Jung was an NIH Ruth L. Kirschstein Postdoctoral Fellow at the RNA Therapeutics Institute at the University of Massachusetts Medical School. Dr. Jung earned a Ph.D. in Chemistry and Biochemistry from the University of Oregon in 2014 as an NIH Ruth L. Kirschstein Predoctoral Fellow. Dr. Jung earned a B.S. in Chemistry from McGill University in 2008. 

Dr. Jung holds over 28 patents and publications in the field of RNA therapeutics and has served on the BOD and SAB of the Oligonucleotide Therapeutics Society and the RNA Society.